V L Rahajamanana1, J L Raboba2, A Rakotozanany2, N J Razafindraibe3, E J P R Andriatahirintsoa4, A C Razafindrakoto2, S A Mioramalala5, C Razaiarimanga6, G G Weldegebriel7, E Burnett8, J M Mwenda9, M Seheri10, M J Mphahlele10, A L Robinson2. 1. Department of Child Health, Teaching Hospital, Centre Hospitalier Universitaire Mère Enfant Tsaralàlana, Antananarivo, Madagascar. Electronic address: v_lalaina@yahoo.fr. 2. Department of Child Health, Teaching Hospital, Centre Hospitalier Universitaire Mère Enfant Tsaralàlana, Antananarivo, Madagascar. 3. Teaching Hospital, Centre Hospitalier Universitaire Andohatapenaka, Antananarivo, Madagascar. 4. Teaching Hospital, Centre Hospitalier Universitaire Anosiala, Antananarivo, Madagascar. 5. National Malaria Country Program, Public Health Ministry, Antananarivo, Madagascar. 6. WHO Country, Madagascar. 7. WHO Inter-Country Support Team: East and Southern Africa (WHO IST/ESA), Harare, Zimbabwe. 8. Foundation for the Centers for Disease Control and Prevention, Division of Viral Diseases, Atlanta, USA. 9. World Health Organization (WHO) Regional Office for Africa (WHO/AFRO), Brazzaville, Congo. 10. Regional Rotavirus Reference Laboratory, SAMRC/Diarrheal Pathogens Research Unit, Department of Virology, Sefako Makgatho Health Sciences University, Pretoria, South Africa.
Abstract
BACKGROUND: Rotavirus vaccine was introduced into the Extended Program on Immunization in Madagascar in May 2014. We analyzed trends in prevalence of all cause diarrhea and rotavirus hospitalization in children <5years of age before and after vaccine introduction and assessed trend of circulating rotavirus genotypes at Centre Hospitalier Universitaire Mère Enfant Tsaralalàna (CHU MET). METHODS: From January 2010 to December 2016, we reviewed the admission logbook to observe the rate of hospitalization caused by gastroenteritis among 19619 children <5years of age admitted at the hospital. In June 2013-December 2016, active rotavirus surveillance was also conducted at CHUMET with support from WHO. Rotavirus antigen was detected by EIA from stool specimen of children who are eligible for rotavirus gastroenteritis surveillance at sentinel site laboratory and rotavirus positive specimens were further genotyped at Regional Reference Laboratory by RT-PCR. RESULTS: Diarrhea hospitalizations decreased after rotavirus vaccine introduction. The median proportion of annual hospitalizations due to diarrhea was 26% (range: 31-22%) before vaccine introduction; the proportion was 25% the year of vaccine introduction, 17% in 2015 and 16% in 2016. Rotavirus positivity paralleled patterns observed in diarrhea. Before vaccine introduction, 56% of stool specimens tested positive for rotavirus; the percent positive was 13% in 2015, 12% in 2016. Diverse genotypes were detected in the pre-vaccine period; the most common were G3P[8] (n=53; 66%), G2P[4] (n=12; 15%), and G1P[8] (n=11; 14%). 6 distinct genotypes were found in 2015; the most common genotype was G2P[4] (n=10; 67%), the remaining, 5, G12[P8], G3[P8], G1G3[P4], G3G12[P4][P8] and G1G3[NT] had one positive specimen each. CONCLUSIONS: Following rotavirus vaccine introduction all-cause diarrhea and rotavirus-specific hospitalizations declined dramatically. The most common genotypes detected in the pre-vaccine period were G3P[8] and G2P[4] in 2015, the post vaccine period.
BACKGROUND: Rotavirus vaccine was introduced into the Extended Program on Immunization in Madagascar in May 2014. We analyzed trends in prevalence of all cause diarrhea and rotavirus hospitalization in children <5years of age before and after vaccine introduction and assessed trend of circulating rotavirus genotypes at Centre Hospitalier Universitaire Mère Enfant Tsaralalàna (CHU MET). METHODS: From January 2010 to December 2016, we reviewed the admission logbook to observe the rate of hospitalization caused by gastroenteritis among 19619 children <5years of age admitted at the hospital. In June 2013-December 2016, active rotavirus surveillance was also conducted at CHUMET with support from WHO. Rotavirus antigen was detected by EIA from stool specimen of children who are eligible for rotavirus gastroenteritis surveillance at sentinel site laboratory and rotavirus positive specimens were further genotyped at Regional Reference Laboratory by RT-PCR. RESULTS: Diarrhea hospitalizations decreased after rotavirus vaccine introduction. The median proportion of annual hospitalizations due to diarrhea was 26% (range: 31-22%) before vaccine introduction; the proportion was 25% the year of vaccine introduction, 17% in 2015 and 16% in 2016. Rotavirus positivity paralleled patterns observed in diarrhea. Before vaccine introduction, 56% of stool specimens tested positive for rotavirus; the percent positive was 13% in 2015, 12% in 2016. Diverse genotypes were detected in the pre-vaccine period; the most common were G3P[8] (n=53; 66%), G2P[4] (n=12; 15%), and G1P[8] (n=11; 14%). 6 distinct genotypes were found in 2015; the most common genotype was G2P[4] (n=10; 67%), the remaining, 5, G12[P8], G3[P8], G1G3[P4], G3G12[P4][P8] and G1G3[NT] had one positive specimen each. CONCLUSIONS: Following rotavirus vaccine introduction all-cause diarrhea and rotavirus-specific hospitalizations declined dramatically. The most common genotypes detected in the pre-vaccine period were G3P[8] and G2P[4] in 2015, the post vaccine period.
Authors: M Iturriza-Gómara; T Dallman; K Bányai; B Böttiger; J Buesa; S Diedrich; L Fiore; K Johansen; M Koopmans; N Korsun; D Koukou; A Kroneman; B László; M Lappalainen; L Maunula; A Mas Marques; J Matthijnssens; S Midgley; Z Mladenova; S Nawaz; M Poljsak-Prijatelj; P Pothier; F M Ruggeri; A Sanchez-Fauquier; A Steyer; I Sidaraviciute-Ivaskeviciene; V Syriopoulou; A N Tran; V Usonis; M VAN Ranst; A DE Rougemont; J Gray Journal: Epidemiol Infect Date: 2010-08-16 Impact factor: 2.451
Authors: Yadira Molto; Jennifer E Cortes; Lucia Helena De Oliveira; Adrianna Mike; Itzel Solis; Onix Suman; Luis Coronado; Manish M Patel; Umesh D Parashar; Margaret M Cortese Journal: Pediatr Infect Dis J Date: 2011-01 Impact factor: 2.129
Authors: T Vesikari; A Karvonen; R Prymula; V Schuster; J C Tejedor; R Cohen; F Meurice; H H Han; S Damaso; A Bouckenooghe Journal: Lancet Date: 2007-11-24 Impact factor: 79.321
Authors: Shabir A Madhi; Nigel A Cunliffe; Duncan Steele; Desirée Witte; Mari Kirsten; Cheryl Louw; Bagrey Ngwira; John C Victor; Paul H Gillard; Brigitte B Cheuvart; Htay H Han; Kathleen M Neuzil Journal: N Engl J Med Date: 2010-01-28 Impact factor: 91.245
Authors: Andrew Duncan Steele; Kathleen M Neuzil; Nigel A Cunliffe; Shabir A Madhi; Pieter Bos; Bagrey Ngwira; Desiree Witte; Stacy Todd; Cheryl Louw; Mari Kirsten; Sanet Aspinall; Leen Jan Van Doorn; Alain Bouckenooghe; Pemmaraju V Suryakiran; Htay Htay Han Journal: BMC Infect Dis Date: 2012-09-13 Impact factor: 3.090
Authors: Mike J Mwanga; Betty E Owor; John B Ochieng; Mwanajuma H Ngama; Billy Ogwel; Clayton Onyango; Jane Juma; Regina Njeru; Elijah Gicheru; Grieven P Otieno; Sammy Khagayi; Charles N Agoti; Godfrey M Bigogo; Richard Omore; O Yaw Addo; Seheri Mapaseka; Jacqueline E Tate; Umesh D Parashar; Elizabeth Hunsperger; Jennifer R Verani; Robert F Breiman; D James Nokes Journal: BMC Infect Dis Date: 2020-07-13 Impact factor: 3.090
Authors: Michelle V Evans; Matthew H Bonds; Laura F Cordier; John M Drake; Felana Ihantamalala; Justin Haruna; Ann C Miller; Courtney C Murdock; Marius Randriamanambtsoa; Estelle M Raza-Fanomezanjanahary; Bénédicte R Razafinjato; Andres C Garchitorena Journal: Proc Biol Sci Date: 2021-03-03 Impact factor: 5.349
Authors: Julia L Raboba; Vonintsoa L Rahajamanana; Emilson P R Andriatahirintsoa; Ainamalala C Razafindrakoto; Andry M Andrianarivelo; Marcellin Nimpa Mengouo; Yolande Vuo Masembe; Goitom G Weldegebriel; Linda de Gouveia; Jason M Mwenda; Annick L Robinson Journal: J Infect Dis Date: 2021-09-01 Impact factor: 5.226
Authors: Emilson Jean P R Andriatahirintsoa; Julia Liliane Raboba; Vonintsoa Lalaina Rahajamanana; Ando Lalaina Rakotozanany; Mengouom M Nimpa; Yolande Vuo Masembe; Goitom Weldegebriel; Linda De Gouveia; Jason M Mwenda; Annick Lalaina Robinson Journal: Clin Infect Dis Date: 2019-09-05 Impact factor: 9.079